Envestnet Portfolio Solutions Inc. Cuts Stake in GSK PLC Sponsored ADR (NYSE:GSK)

Envestnet Portfolio Solutions Inc. reduced its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 64.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,060 shares of the pharmaceutical company's stock after selling 28,957 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in GSK were worth $622,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Dodge & Cox raised its holdings in GSK by 0.5% during the 4th quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company's stock valued at $2,314,672,000 after acquiring an additional 353,749 shares during the period. FMR LLC grew its position in shares of GSK by 82.1% in the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock valued at $1,786,475,000 after purchasing an additional 23,814,104 shares in the last quarter. Primecap Management Co. CA raised its stake in shares of GSK by 70.1% during the 4th quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock valued at $854,349,000 after purchasing an additional 10,407,905 shares during the period. Fisher Asset Management LLC lifted its holdings in GSK by 1.4% during the 4th quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company's stock worth $637,061,000 after purchasing an additional 259,867 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in GSK by 0.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company's stock worth $255,914,000 after purchasing an additional 35,134 shares in the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Price Performance

Shares of NYSE GSK traded down $0.20 during midday trading on Monday, hitting $38.38. 4,803,585 shares of the company's stock were exchanged, compared to its average volume of 4,905,140. The business's fifty day moving average price is $38.86 and its two-hundred day moving average price is $36.97. The company has a market cap of $78.58 billion, a price-to-earnings ratio of 19.78, a PEG ratio of 1.35 and a beta of 0.52. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.21. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $44.67.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The business had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. GSK had a net margin of 9.89% and a return on equity of 48.82%. The business's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.43 EPS. As a group, research analysts forecast that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be paid a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a yield of 4.39%. The ex-dividend date is Friday, May 16th. This is a boost from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio is currently 87.11%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. BNP Paribas started coverage on GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target on the stock. Wall Street Zen cut shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a report on Monday, April 28th. Finally, Berenberg Bank reissued a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.